Your session is about to expire
← Back to Search
Phosphodiesterase-4 (PDE-4) Inhibitor
ARQ-154 foam 0.3% for Plaque Psoriasis
Phase 2
Waitlist Available
Research Sponsored by Arcutis Biotherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and weeks 2, 4, 8
Awards & highlights
Summary
This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis
Eligible Conditions
- Plaque Psoriasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline and weeks 2, 4, 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and weeks 2, 4, 8
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants Achieving Success in the Scalp Investigator Global Assessment (S-IGA) Scale
Secondary outcome measures
Psoriasis
Number of Participants Achieving Body Investigator Global Assessment (B-IGA) Success at Week 8
Number of Participants Achieving PSSI-90
+3 moreSide effects data
From 2020 Phase 2 trial • 304 Patients • NCT041280071%
Testicular torsion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Roflumilast Foam 0.3%
Vehicle Foam
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: ARQ-154 foam 0.3%Experimental Treatment1 Intervention
active
Group II: ARQ foam VehicleRQ-154 foam VehiclePlacebo Group1 Intervention
placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Roflumilast foam 0.3%
2020
Completed Phase 2
~310
Find a Location
Who is running the clinical trial?
Arcutis Biotherapeutics, Inc.Lead Sponsor
21 Previous Clinical Trials
7,337 Total Patients Enrolled
David Berk, MDStudy DirectorArcutis Biotherapeutics
21 Previous Clinical Trials
8,331 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger